Bladder Cancer New Indication: Neoadjuvant Durvalumab with CISplatin/Gemcitabine for Upper GU Tract Cancer Ulas D. Bayraktar, MD 2025-05-05
Biliary Tract Cancer New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-11-20
Bladder Cancer New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-06-14
